SEARCH

SEARCH BY CITATION

References

  • 1
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295306.
  • 2
    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG: Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7:17371740.
  • 3
    Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin M: Antiphospholipid Syndrome Clinical Research Task Force report. Lupus. 2011; 20(2):219224.
  • 4
    Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M: Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-β 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus 2010; 19:613619.
  • 5
    Erkan D, Lockshin M: Non-criteria manifestations of antiphospholipid syndrome. Lupus 2010; 19:424427.
  • 6
    Erkan D, Derksen WJ, Kaplan V, Sammaritano L, Pierangeli SS, Roubey R, Lockshin M: Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis 2005; 64:13211325.
  • 7
    Ruffatti A, Tonello M, Visentin MS, Bontadi A, Hoxha A, De Carolis S, Botta A, Salvi S, Nuzzo M, Rovere-Querini P, Canti V, Mosca M, Mitic G, Bertero MT, Pengo V, Boffa MC, Tincani A: Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011; 50:16841689.
  • 8
    Ruffatti A, Calligaro A, Hoxha A, Trevisanuto D, Ruffatti AT, Gervasi MT, Cuffaro S, Pengo V, Punzi L: Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 2010; 62:302307.
  • 9
    Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter TF, Sammaritano L, Stephenson MD, Buyon J, Salmon J: Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64:23112318.
  • 10
    Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253257.
  • 11
    Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:15841589.
  • 12
    Lassere M, Empson M: Treatment of antiphospholipid syndrome in pregnancy: a systematic review of randomized therapeutic trials. Thromb Res 2004; 114:419426.
  • 13
    Erkan D, Lockshin MD: New approaches for managing antiphospholipid syndrome. Nature Clin Pract Rheumatol 2009; 5:160170.
  • 14
    Salmon JE, Girardi G, Lockshin MD: The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 2007; 3(3):140147.
  • 15
    De la Torre YM, Pregnolato F, D'Amelio F, Grossi C, Di Simone N, Pasqualini F, Nebuloni M, Chen P, Pierangeli S, Bassani N, Ambrogi F, Borghi MO, Vecchi A, Locati M, Meroni PL: Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid binding site. Implications for human fetal loss. J Autoimm 2012; 38:J209J215. Epub 2011 Dec 22.